Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety
- PMID: 20348274
- PMCID: PMC3227960
- DOI: 10.1634/theoncologist.2009-0325
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety
Abstract
Background: Isolated limb perfusion (ILP) involves the administration of chemotherapy drugs directly into a limb involved by locoregional metastases. Unresectable locally advanced melanoma of the limbs represents one of the clinical settings in which ILP has demonstrated benefits.
Methods: A systematic review of the literature on ILP for patients with unresectable locally advanced melanoma of the limbs was conducted. MEDLINE, EMBASE, and Cochrane database searches were conducted to identify studies fulfilling the following inclusion criteria: hyper- or normothermic ILP with melphalan with or without tumor necrosis factor (TNF) or other drugs providing valid data on clinical response, survival, or toxicity. To allocate levels of evidence and grades of recommendation the Scottish Intercollegiate Guidelines Network system was used.
Results: Twenty-two studies including 2,018 ILPs were selected with a clear predominance of observational studies (90.90%) against experimental studies (9.10%). The median complete response rate to ILP was of 58.20%, with a median overall response rate of 90.35%. ILP with melphalan yielded a median complete response rate of 46.50%, against a 68.90% median complete response rate for melphalan plus TNF ILP. The median 5-year overall-survival rate was 36.50%, with a median overall survival interval of 36.70 months. The Wieberdink IV and V regional toxicity rates were 2.00% and 0.65%, respectively.
Conclusions: ILP is effective in achieving clinical responses in patients with unresectable locally advanced melanoma of the limbs. The disease-free and overall survival rates provided by ILP are acceptable. ILP is safe, with a low incidence of severe regional and systemic toxicity.
Conflict of interest statement
Section editors
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Figures


Similar articles
-
Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.J Surg Oncol. 2014 Mar;109(4):348-51. doi: 10.1002/jso.23553. J Surg Oncol. 2014. PMID: 24522939
-
Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma.Ann Surg Oncol. 2025 Aug;32(8):5397-5401. doi: 10.1245/s10434-025-17403-9. Epub 2025 May 10. Ann Surg Oncol. 2025. PMID: 40348927
-
Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.Lancet Oncol. 2003 Jun;4(6):359-64. doi: 10.1016/s1470-2045(03)01117-3. Lancet Oncol. 2003. PMID: 12788409
-
Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis.Ann Surg Oncol. 2017 Dec;24(13):3803-3810. doi: 10.1245/s10434-017-6109-7. Epub 2017 Oct 11. Ann Surg Oncol. 2017. PMID: 29022281
-
A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients.J Surg Res. 2021 Dec;268:737-747. doi: 10.1016/j.jss.2021.05.054. Epub 2021 Jul 10. J Surg Res. 2021. PMID: 34253376
Cited by
-
Leakage through the bone-marrow during isolated limb perfusion in the lower extremity.J Surg Case Rep. 2019 Apr 3;2019(4):rjz090. doi: 10.1093/jscr/rjz090. eCollection 2019 Apr. J Surg Case Rep. 2019. PMID: 30967928 Free PMC article.
-
In-transit metastatic cutaneous melanoma: current management and future directions.Clin Exp Metastasis. 2022 Feb;39(1):201-211. doi: 10.1007/s10585-021-10100-3. Epub 2021 May 17. Clin Exp Metastasis. 2022. PMID: 33999365 Review.
-
Therapeutic Treatment Options for In-Transit Metastases from Melanoma.Cancers (Basel). 2024 Sep 3;16(17):3065. doi: 10.3390/cancers16173065. Cancers (Basel). 2024. PMID: 39272923 Free PMC article. Review.
-
Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis.Melanoma Manag. 2022 Jun 30;9(2):MMT61. doi: 10.2217/mmt-2021-0006. eCollection 2022 Jun. Melanoma Manag. 2022. PMID: 35813184 Free PMC article.
-
Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.Ann Surg Oncol. 2019 Apr;26(4):1055-1062. doi: 10.1245/s10434-018-07143-4. Epub 2019 Jan 7. Ann Surg Oncol. 2019. PMID: 30617871 Free PMC article.
References
-
- Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg. 1996;83:1319–1328. - PubMed
-
- Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol. 1988;14:157–163. - PubMed
-
- Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical